Compare CubeSmart (CUBE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Neurocrine Biosciences Inc — how do they compare? CubeSmart trades at $40.56 (market cap $9.19B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.51B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and CubeSmart pays a 5.22% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CUBE | NBIX | |
|---|---|---|
Market Cap | $9.19B | $17.51B |
Sector | Real Estate | Health |
52-Week High | $42.34 | $180.55 |
52-Week Low | $35.36 | $123.10 |
Enterprise Value | $12.69B | $16.60B |
Dividend Yield | 5.22% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
